SULFADOXINE, 500mg / PYRIMETHAMINE, 25mg, disp. tab.

STD DORASULP5TD

Valid Article

6.5.3.1 - For curative treatment
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.5.3.2 - For chemoprevention
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01BD51
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

SULFADOXINE / PYRIMETHAMINE (SP)

Therapeutic Action

Fixed-dose combination (FDC) of two antimalarials

Indications

Intermittent preventive treatment of malaria during pregnancy (IPTp-PS) from the second trimester onwards in areas of moderate to high malaria transmission in Africa

Instructions for use

The 250 mg/12.5 mg dosage is intended for paediatric use.

The 500 mg dispersible tablet is preferred to the normal 500 mg tablet.

The resistance to sulfadoxine/pyrimethamine is more and more frequent.

Precautions for Use

Contra-indicated during the first trimester of pregnancy (risk of neural tube defects).

Do not use in combination with co-trimoxazole.

Storage

Below 25°C ‐ Protect from sunlight